NAD+ vs NMN: Different Molecules, Different Evidence

Key Takeaways

• NAD+ and NMN are related molecules, not interchangeable names. NMN is a precursor used in NAD+ production. (Yoshino et al., 2021, Science)
• Oral NMN research does not establish the effects of injected NAD+.
• A biological measurement is different from an outcome such as improved function or a longer life.
• Compare the exact formulation, route, study population and safety information before drawing a conclusion.

Start with the names

NAD+ stands for nicotinamide adenine dinucleotide. It participates in cellular metabolic processes. NMN stands for nicotinamide mononucleotide, a molecule involved in a pathway that produces NAD+. The relationship explains why they appear together in research discussions, but it does not make them the same intervention. (Yoshino et al., 2021, Science)

You may also encounter NR, or nicotinamide riboside. NR is another NAD+ precursor and has its own research literature. A study of NR should be identified as an NR study, rather than silently presented as evidence for NMN or an NAD+ injection. (Martens et al., 2018, Nature Communications)

To compare them, look at what researchers studied, who participated and what they found. That question becomes especially important when a product description moves from cellular biology to a promise about daily energy or healthy aging.

What one NMN trial can tell us

Yoshino and colleagues studied oral NMN in a small randomized trial involving postmenopausal women with prediabetes and overweight or obesity. The investigators reported improved muscle insulin sensitivity in that specific setting. They did not establish a longer lifespan or broad benefits across all tissues and outcomes. (Yoshino et al., 2021, Science)

That finding is worth understanding at its actual scale. It is not a study of NAD+ injections, not a test of Liv’s formulations and not proof that every person considering a longevity treatment would have the same result.

When reading a summary, look for the study’s boundaries before focusing on a favorable result. Ask whether the participants resemble the audience addressed by the claim, whether there was a comparison group and whether the measured outcome is the outcome being advertised.

Why the measured outcome matters

A study can show that an intervention changes a molecule or a metabolic measurement without establishing how someone will feel. That does not make the measurement meaningless. It means the result answers a narrower question.

The difference is easy to lose in phrases such as “supports energy.” Cellular processes involving energy are not the same outcome as a person reporting less fatigue. A claim about the latter needs evidence measuring that experience, rather than a diagram of the former.

NR findings belong to NR

In a randomized trial, Martens and colleagues found that oral NR increased NAD+ in the studied adults and was well tolerated over the study period. The study is relevant to the formulation and conditions tested. It does not establish that every NAD-related product has the same effects or long-term safety. (Martens et al., 2018, Nature Communications)

This is a useful example of why references need to be read beyond their titles. A source can be legitimate and still be used to support the wrong product. Check whether the article identifies the ingredient correctly and keeps the route clear.

Our NAD+ supplement guide offers additional terminology. Use it to form questions, rather than assuming every product discussed under the NAD+ umbrella has a shared evidence base.

Injections raise a different set of questions

Grant and colleagues conducted a pilot study examining changes in NAD-related metabolites during an intravenous NAD+ infusion. The study’s purpose and route were specific. It was not a demonstration that NAD+ injections improve everyday energy, extend life or establish the effects of subcutaneous use. (Grant et al., 2019, Frontiers in Aging Neuroscience)

“Injection” can conceal important differences. Intravenous delivery, delivery into muscle and delivery under the skin are different routes. Evidence from one cannot simply be assigned to another. The exact product and administration route should be part of any clinical discussion.

If you’re considering an injectable option, read the NAD+ injection overview with that distinction in mind. Ask the provider which evidence applies to the proposed route and which expected outcomes remain unestablished.

Compounding and sterility deserve their own discussion

FDA has reminded compounders of the need to use ingredients suitable for sterile preparation after reports involving NAD+ injectable products. The agency described adverse events including severe chills, shaking, vomiting and fatigue, with some requiring medical attention. The alert does not establish an adverse-event rate or identify Liv as involved. (FDA, 2024, sterile-compounding safety communication)

The warning is a reason to ask about the exact preparation, dispensing pharmacy and instructions for reporting problems. It is not a basis for assuming all products are identical or that the absence of a published report proves safety.

Compounded medications are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing. That approval distinction remains relevant even when a molecule has been studied in another setting. (FDA, compounding questions and answers (accessed 2026))

Compare questions before comparing products

A useful comparison can be organized around four questions. First, what do you want help with? A broad interest in longevity is different from a specific symptom that needs evaluation.

Second, what evidence addresses that goal? Ask for the human outcome, the population and the exact intervention. If the answer concerns a molecular marker, clarify what it can and cannot tell you.

Third, what is known about risks and uncertainty? Ask about the proposed route, other medicines, relevant medical history and what should prompt a call. No route should be described as risk-free merely because the underlying molecule occurs naturally in the body.

Fourth, what would make the plan worth continuing or reconsidering? Agree on the purpose of follow-up before starting, rather than trying to interpret every day-to-day change afterward.

Read an evidence comparison in four separate parts

A useful NAD+ versus NMN comparison should keep identity, route, outcome and safety separate. Identity tells you which molecule was studied. Route tells you how participants received it. Outcome tells you what changed. Safety tells you what the study was able to observe within its size and duration.

A favorable answer in one part does not settle the others. Correctly identifying NMN as a precursor does not establish its clinical benefits. Showing a change after oral use does not establish the result of an injection. Reporting tolerability during a short trial does not answer every question about longer use.

You can use those four parts when a source looks persuasive but the conclusion feels much broader than the study. Ask the clinician to walk through each part for the exact option being discussed. If there is no matching study for the proposed route or outcome, that uncertainty belongs in the decision.

Place the existing studies beside one another carefully

The Yoshino trial involved oral NMN and a defined group of postmenopausal women. The Martens trial involved oral NR in a different population. The Grant pilot involved intravenous NAD+ and an analysis of metabolites. These are three different research questions, not three entries in a head-to-head product contest. (Yoshino et al., 2021, Science) (Martens et al., 2018, Nature Communications) (Grant et al., 2019, Frontiers in Aging Neuroscience)

Because the designs differ, lining up their favorable findings does not establish which intervention is best. A direct comparative claim would need an appropriate comparison, rather than a selection of separate studies with different participants and outcomes.

This is especially relevant when a product page uses several references together. More references do not repair a mismatch between the intervention studied and the product offered. The useful test is whether each source supports the nearby statement.

You do not need to choose between dismissing all the research and accepting every proposed benefit. You can recognize a specific finding, understand why it is interesting and still decide that it does not yet answer the question most important to your own care.

Match the evidence to your goal

NAD+ versus NMN is not a contest with one universal answer. The available studies address different interventions and different questions. A responsible discussion may end with more evaluation, consideration of another approach or a decision not to pursue either option.

If you would like to explore your goals with a provider, start with Liv’s Healthy Aging pathway. Treatment is subject to provider approval and individual eligibility, and availability varies by state. An intake is not evidence that an NAD-related prescription is needed.

Frequently Asked Questions